02315.HK
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 38.30
−8.81%Year over year
Reported trailing growth
- Revenue
- +42.8%
- EBITDA
- +42.3%
- EBIT
- +71.7%
- EPS
- +149.1%
- Free cash flow
- -59.3%
- Operating cash flow
- +6.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +37.2%
- EBITDA
- +38.1%
- EBIT
- +69.5%
- Net income
- +416.4%
- EPS
- +410.1%
- Free cash flow
- +62.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026